Study of OT-101 in Treating Myopia

Status Active, not recruiting

Clinical Trial Summary

This is a phase III, randomized, double-masked, placebo-controlled, parallel-group, multicenter safety, tolerability, and efficacy study of atropine sulfate 0.01% (OT-101) as an investigational treatment for myopia in pediatric subjects

Clinical Trial Description

This is a phase III, randomized, double-masked, placebo-controlled, parallel-group, multi-center study to evaluate the safety tolerability and efficacy of OT-101 (Atropine 0.01%) Ophthalmic Solution in treating the progression of myopia in pediatric subjects that will enroll approximately 678 pediatric subjects with myopia in total. Subjects will be stratified by age and refractive error. This study consists of 11 visits over the course of approximately 4 years and can be broken down in the 3 stages: Screening (Days -14 to -1), Stage 1 (Day 1 to Year 3), and Stage 2 (Year 3 to Year 4). In stage 1, subjects will be randomized in a 2:1 manner to OT-101 Ophthalmic Solution: Placebo. Subjects will be dosed with one drop of study treatment per eye once daily at bedtime for 3 years. In stage 2, subjects will be re-randomization 1:1 will occur at Visit 9 (Month 36). At re-randomization, subjects who had been assigned to OT-101 Ophthalmic Solution will be randomized in a 1:1 ratio to continue on OT-101 Ophthalmic Solution or switch to placebo. Subjects who had been assigned to placebo will continue with placebo. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04770610
Study type	Interventional
Source	Ocumension (Hong Kong) Limited
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	April 1, 2021
Completion date	April 2027

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05919654` - Clinical Evaluation of MyoCare in Europe (CEME)	N/A
Recruiting	`NCT03402100` - Eye Drops Study for Myopia Control in Schoolchildren	N/A
Recruiting	`NCT03865160` - Low-dose Atropine for Myopia Control in Children	Phase 2/Phase 3
Recruiting	`NCT06088225` - Myopia Preventing With Distance-image Screen	N/A
Not yet recruiting	`NCT06085430` - Kubota Glass Parameter Refinement Study	N/A
Not yet recruiting	`NCT06405711` - To Evaluate the Efficacy and Safety of an Defocus Lens in Slowing the Progression of Myopia	N/A
Recruiting	`NCT05881655` - Slow Myopia Progression With Different Irradiance Light	N/A
Recruiting	`NCT05761379` - Clinical Study of Light Therapy to Control Myopia Progression in Children	N/A
Not yet recruiting	`NCT05760911` - Myopia Prevention Through Monitoring and Motivating Outdoor Activities With Smartwatches	N/A
Recruiting	`NCT04722874` - Repeated Low-Level Red-Light Therapy and Orthokeratology in Fast-progressing Myopia Control	N/A
Not yet recruiting	`NCT06221592` - Differences and Wearing Safety and Comfort of New Defocus Incorporated Multiple Segments Spectacle Lenses	N/A
Completed	`NCT04806711` - Eleven Years of Menicon Z Night Contact Lens Wear in Reducing Myopia Progression in Children	N/A
Completed	`NCT04806698` - Long-term Efficacy of Orthokeratology Contact Lens Wear in Controlling the Progression of Childhood Myopia	N/A
Completed	`NCT04806763` - Myopia Control With Orthokeratology Contact Lenses in Spain	N/A
Recruiting	`NCT05894382` - Double Helix Design Defocus Lens Spectacle (RACE) for Myopia Control	N/A
Completed	`NCT05683535` - Adverse Events Related to Low Dose Atropine
Completed	`NCT05300321` - DIMS-myopia Progression ADN Axial Length Growth	N/A
Withdrawn	`NCT03519490` - Can Distance Center and Near Center Multifocal Contact Lenses Control Myopia Progression in Children?	N/A
Completed	`NCT05372991` - Safety, Tolerability and Pharmacodynamics Evaluation of CBT-009 Eye Drop	Phase 1/Phase 2
Active, not recruiting	`NCT05373693` - Myopia-control Efficacy by Peripheral Defocus Lens (PDL)	N/A